clinical trials for semaglutide Long-term weight loss effects of in obesity without diabetes in the SELECT trial American Federation of Medical Research

Yes, the FDA has approved semaglutide (Wegovy) and liraglutide (Saxenda) for adolescents aged 12 years and older who have a BMI at or above the 95th percentile for their age and sex

No membership fees

The biology underlying both appears to be the same: a shared pathway, with one medication class affecting it

Nonarteritic anterior ischemic optic neuropathy is a rare condition caused by reduced blood flow to the optic nerve, leading to sudden and sometimes permanent vision loss

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for two primary indications: type 2 diabetes management and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity